ArticleERJ open research2025
Guideline-concordant inhaled medication use in COPD: a systematic review of definitions used in administrative health data.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- GOLD-concordant inhaled maintenance therapy at hospital discharge after hospitalisation for severe COPD exacerbation: a multicentre retrospective observational study.The Lancet regional health. Europe · 2026Article
- Article
- Inhaled corticosteroid overuse and deprescribing eligibility in COPD (iCODEC Study): a nationwide cross-sectional analysis in China.NPJ primary care respiratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Assessments of guideline-discordant use of maintenance inhaled therapies for COPD in administrative health data are common but restricted by lack of patient characteristics. We systematically reviewed definitions of guideline-concordant and guideline-discordant maintenance inhaled medication use applied to administrative health data. Methods: We searched MEDLINE and Embase from January 2000 to September 2024 for studies that 1) used administrative health data to identify adults with COPD who were prescribed long-acting bronchodilators (LABDs) or inhaled corticosteroids (ICS) for outpatient treatment; 2) defined maintenance inhaled medication use as guideline-concordant and/or guideline-discordant at the patient level. We developed standardised definitions for claims data aligned with management recommendations and conducted a meta-analysis to assess the proportion of patients with guideline-concordant and guideline-discordant medication use. Results: We screened 4578 records and included 20 studies. There were 22 unique definitions of guideline-concordance or discordance, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations. The most common measurements were 1) guideline-discordant ICS use (n=10); 2) guideline-concordant LABDs use (n=8); and 3) guideline-concordant ICS use, focusing on ICS alone (n=4) regardless of LABDs or with LABDs (n=6). Given that acute exacerbations of COPD (AECOPD) was the most commonly used criterion and aligned with recommendations, we developed an AECOPD risk-based definition. Pooled analysis showed 50% guideline-concordant LABDs use and 45% guideline-discordant ICS use across populations. Conclusions: Definitions of guideline-concordant LABDs use and guideline-discordant ICS use in administrative health data are largely congruent with GOLD. AECOPD risk-based definitions provide a generalisable approach for assessing guideline-concordance in administrative data.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.